ΔΗΜΟΣΙΕΥΣΕΙΣ: 1. N. Touroutoglou: Results of doctoral thesis are incorporated into the pharmacokinetics chapter in the German pharmacology textbook: pp. 30-34m W. Forth, D. Henschler, W. Rummel; Allgemeine and Spezielle Pharmakologie and Toxikologie, Wissenschaftsverlag, 5. Aufl. Mannheim, 1987 2. Pfluger, T., Wendt, T., Touroutoglou, N.: Retrobulbar irradiation of endocrine opthalmopathy. A comparison between 10 and 16 Gy total dose. Strahlenther-Onkol 1990, 166(10)p 673-7 3. N. Touroutoglou: M. Dimopoulos, A. Younes, Hess M., Cox, J., Cabanillas, F., Sarris, A.: Testicular Lymphoma: Late relapses and poor outcome despite doxorubicin based chemotherapy. J Clin Oncol 13, 6:1361-1367, 1995 4. Touroutoglou, N.: Pazdur, R.: Thymidylate synthase inhibitors. Clin Cancer Res 2: 227-243, 1996 5. Touroutoglou, N.: Clinical Results of a Pharmacodynamically-Based Strategy for Higher Dosign of Gemcitabine in Patients with Solid Tumors. Ann Oncol 9:1-6, 1998 6. Treon, SP.., Hansen, M.,., Branagan, A., Verselis, S, Emmanouilides, C., Kimby, E, Frankel, SR., Touroutoglou, N, Turnbull,B Anderson, KC, Maloney, DG, Fox, EA. Polymorphisms in FC GAMMA RIIIA (CD16) Receptor Expression are Associated with Clinical Response to Rituximab in Waldenstrom’s Macroglobulinemia. J Clin Oncol 23 3:474-481, 2005. POSTER PRESENTATION: Touroutoglou N, Von Horstig R, Kurz J, Shuhman G: The binding of anionic and cationic drugs to human tissues. Advances in Pharmacokinetics, Braunschweig 1986. ΚΕΦΑΛΑΙΟ ΣΕ ΒΙΒΛΙΟ: Touroutoglou N, Arcenas A, Ajani J: Neuroendocrine, Tumors of the GI Tract. Medical Oncology: A Comprehensive Review, Second Edition. Richard Pazdur (Editor) PRR, Hyntington, NY, January 1996. ABSTRACTS: 1. Touroutoglou N, A Sarris, A. Younes, Dimopoulos M, Hess M, Cabanillas F. Testicular large cell lymphoma (TLCL): A retrospective study of 25 patients. Proc. Am. Soc. Clin. Oncol. 13:388, Abstr 1322, 1994. 2. Pazdur R, Diaz-Canton E, Meyers C, Abbruzzese J, Patt Y, Rivera E, Touroutoglou, N, Edwards K, Bready B, Ajani JA: Phase II Trial of CI-980 in Metastatic Colorectal Carcinoma Patients. Proc. Am. Soc. Clin. Oncol. 14: A511, 1995. 3. Lee J, Komaki R, Touroutoglou N, et al. Erythropoietin (EPO) prevents anemia during concurrent chemoradiation therapy (RT) for locally advanced inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998; 17:463a 4. C. Emmanouilides, N. Touroutoglou, D. Diamandidis, L.Fayad, C. Wolf, M. Territo. Unrelated Allogenic Non-myeloablative Bone Marrow Transplant is feasible and effective. Proc. Am Soc Hem; 96:11, A5311, 2000 5. Touroutoglou N, Wierman AM, Diamandidis D, Fayad L, Gollard R, Boedeker H, Nagy MN, Klimek S, Giron M, Nevada Cancer Center, Las Vegas NV. Neutrexin (TMTX), 5-Flourouracil (5FU) and Leucovorin (LCV), (NFL) in patients previously untreated with metastatic colorectal cancer (CRC). American Society of Clinical Oncology, May 2001. 6. SP Treon, M Hansen, AR Branagan, C Emmanouilides, E Kimby, S Frankel, N Touroutoglou, D Maloney, KC Anderson, EA Fox. Polymorphisms in FcGRIIIA (CD!^) Receptor Expression are Associated with Clinical Response to Rituximab in Waldenstrom’s Macroglobulinemia. Proc. Am Soc. Clin Onc #6556, 2004 7. Treon, SP., Fox, EA., Hansen, M., Verselis, S., Branagan, A., Touroutoglou, N., Maloney, DG., Frankel, SR., Anderson, KC., Emmanouilides, C., Kimby, E. Polymorphisms in FC GAMMA RIIIA (CD16) Receptor Expression are Associated with Clinical Response to Rituximab in Waldenstrom’s Macroglobulinemia. Blood 2002 Nov 16 100(11) p 2251